Synapse - Works

Results (5608)

The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: Using clinical judgement over treatment criteria

Journal Article

Apolo, A. B.; Bellmunt, J.; Cordes, L.; Gupta, S.; Powles, T.; Rosenberg, J. E.; Van Der Heijden, M. S.
ESMO Open (2024)

Fulltext@MSK | Save

Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer

Journal Article

Lenis, A. T.; Ravichandran, V.; Brown, S.; Alam, S. M.; Katims, A.; Truong, H.; Reisz, P. A.; Vasselman, S.; Nweji, B.; Autio, K. A.; more...
Clinical Cancer Research (2024)

Fulltext@MSK | Save

Assessment of supporting evidence and postmarketing requirements for therapeutic indications with Real-Time Oncology Drug Review, 2018-2023

Meeting Abstract

Mooghali, M.; Mohammad, A.; Wallach, J. D.; Mitchell, A. P.; Ross, J. S.; Ramachandran, R.
Value in Health (2024)

Fulltext@MSK | Save

Real-world treatment patterns and clinical outcomes of metastatic renal cell carcinoma patients post immune-oncology (IO) and vascular endothelial growth factor (VEGF) receptor targeted therapies

Meeting Abstract

Shah, N.; Sura, S.; Shinde, R.; Wentworth, C.; Conkling, P.; Bupathi, M.; Perini, R.; Vickery, D.; Motzer, R.
The Oncologist (2024)

Fulltext@MSK | Save

Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial

Meeting Abstract

Atkins, M. B.; Escudier, B.; McDermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Plimack, E. R.; Porta, C.; George, S.; Powles, T.; more...
The Oncologist (2024)

Fulltext@MSK | Save

A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan (WELIREG(TM)) in patients with advanced or metastatic renal cell carcinoma, NCT06234605

Meeting Abstract

McKay, R. R.; Garmezy, B.; Barata, P.; Ornstein, M.; Shah, N. J.; Hammers, H.; Hutson, T. E.; Chisamore, M.; Karim, D.; Mattson, P.; more...
The Oncologist (2024)

Fulltext@MSK | Save

Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39

Meeting Abstract

Bedke, J.; Van Der Heijden, M. S.; Powles, T.; Valderrama, B. P.; Kikuchi, E.; Iyer, G.; Vulsteke, C.; Swami, U.; Castellano, D.; Sarwar, N.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39

Meeting Abstract

Van Der Heijden, M. S.; Gupta, S.; Bedke, J.; Valderrama, B. P.; Kikuchi, E.; Iyer, G.; Loriot, Y.; Dawson, N. A.; Hoffman-Censits, J. H.; Mar, N.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)-2-year event-free survival and safety data for Cohort H

Meeting Abstract

O'Donnell, P. H.; Hoimes, C. J.; Rosenberg, J. E.; Petrylak, D. P.; Mar, N.; Barata, P. C.; Srinivas, S.; Gourdin, T. S.; Henry, E.; Bilen, M. A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies

Meeting Abstract

Pant, S.; Park, J. O.; Su, W. C.; Schuler, M. H.; Loriot, Y.; Iyer, G.; Doi, T.; Qin, S.; Tabernero, J.; Prenen, H.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save